Keywords: Cephalon, Valeant, Rejects merger

Cephalon turns down Valeant’s hostile $5.7 billion takeover bid

Article | 06 April 2011

Print This

US drugmaker Cephalon (Nasdaq: CEPH) last evening said that, after a thorough review, its board of directors has formally rejected ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in